1
|
de Aguirre PM, Carlos S, Pina-Sánchez M, Mbikayi S, Burgueño E, Tendobi C, Chiva L, Holguín Á, Reina G. High pre-Delta and early-Omicron SARS-CoV-2 seroprevalence detected in dried blood samples from Kinshasa (D.R. Congo). J Med Virol 2024; 96:e29529. [PMID: 38516764 DOI: 10.1002/jmv.29529] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2023] [Revised: 02/02/2024] [Accepted: 03/01/2024] [Indexed: 03/23/2024]
Abstract
Studies on the impact of the COVID-19 pandemic in sub-Saharan Africa have yielded varying results, although authors universally agree the real burden surpasses reported cases. The primary objective of this study was to determine SARS-CoV-2 seroprevalence among patients attending Monkole Hospital in Kinshasa (D.R. Congo). The secondary objective was to evaluate the analytic performance of two chemiluminescence platforms: Elecsys® (Roche) and VirClia® (Vircell) on dried blood spot samples (DBS). The study population (N = 373) was recruited in two stages: a mid-2021 blood donor cohort (15.5% women) and a mid-2022 women cohort. Crude global seroprevalence was 61% (53.9%-67.8%) pre-Delta in 2021 and 90.2% (84.7%-94.2%) post-Omicron in 2022. Anti-spike (S) antibody levels significantly increased from 53.1 (31.8-131.3) U/mL in 2021 to 436.5 (219.3-950.5) U/mL in 2022 and were significantly higher above 45 years old in the 2022 population. Both platforms showed good analytic performance on DBS samples: sensitivity was 96.8% for IgG (antiN/S) (93.9%-98.5%) and 96.0% (93.0%-98.0%) for anti-S quantification. These results provide additional support for the notion that exposure to SARS-CoV-2 is more widespread than indicated by case-based surveillance and will be able to guide the pandemic response and strategy moving forward. Likewise, this study contributes evidence to the reliability of DBS as a tool for serological testing and diagnosis in resource-limited settings.
Collapse
Affiliation(s)
| | - Silvia Carlos
- Department of Preventive Medicine and Public Health, Universidad de Navarra, Pamplona, Spain
- Instituto de Investigación Sanitaria de Navarra (IdiSNA) Irunlarrea, 3, Pamplona, Spain
| | | | - Samclide Mbikayi
- Centre Hospitalier Monkole, Kinshasa, Democratic Republic of Congo
| | - Eduardo Burgueño
- Centre Hospitalier Monkole, Kinshasa, Democratic Republic of Congo
| | - Céline Tendobi
- Centre Hospitalier Monkole, Kinshasa, Democratic Republic of Congo
| | - Luis Chiva
- Clínica Universidad de Navarra, Pamplona, Spain
| | - África Holguín
- Laboratorio Epidemiología Molecular VIH-1, Hospital Ramón y Cajal -IRYCIS y CIBERESP-RITIP, Madrid, Spain
| | | |
Collapse
|
2
|
Ige FA, Ohihoin GA, Osuolale K, Dada A, Onyia N, Johnson A, Okwuraiwe AP, Odediran O, Liboro G, Aniedobe M, Mogaji S, Nwaiwu SO, Akande IR, Audu RA, Salako BL. Seroprevalence of SARS-CoV-2 IgG among healthcare workers in Lagos, Nigeria. PLoS One 2023; 18:e0292440. [PMID: 37796780 PMCID: PMC10553227 DOI: 10.1371/journal.pone.0292440] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2023] [Accepted: 09/20/2023] [Indexed: 10/07/2023] Open
Abstract
Healthcare workers (HCWs) are disproportionately infected with SARS-CoV-2 when compared to members of the general public; estimating the seroprevalence of SARS-CoV-2 antibody and SARS-CoV-2 infection rate among HCWs is therefore crucial. This study was carried out in four health facilities in Lagos Nigeria to determine the prevalence of IgG antibodies (seroprevalence) and SARS-CoV-2 active infection rate via a positive rtPCR result, the cross-sectional study was conducted between December 2020 and July 2021. Nasopharyngeal and blood samples were collected from HCWs and screened for SARS-CoV-2 infection using the rtPCR technique and antibody using the Abbott anti-SARS-CoV-2 IgG CMIA assay, respectively. Demographic and occupational exposures data were obtained and analysed using descriptive and inferential statistics, variables significant via inferential statistics were subjected to a multivariate analysis. A total of 413 participants were enrolled, with a mean age in years of 38.4±11.0. The seroprevalence was 30.9% (115/372) while 63/395 (15.9%) were actively infected with the virus. HCWs whose job role had direct contact with patients had a higher percentage of SARS-CoV-2 infection when compared with those not in direct contact, also being a health care worker was significantly associated with getting a positive COVID-19 PCR result. In conclusion the SARS-CoV-2 seroprevalence seen in this study was higher than national serosurvey estimates indicating HCWs are at higher risk of COVID-19 infection when compared to the general public. Vaccination and effective implementation of infection control measures are important to protect HCWs.
Collapse
Affiliation(s)
- Fehintola Anthonia Ige
- Center for Human Virology and Genomics, Nigerian Institute of Medical Research, Yaba, Lagos, Nigeria
| | - Gregory Aigbe Ohihoin
- Clinical Science Department, Nigerian Institute of Medical Research, Yaba, Lagos, Nigeria
| | - Kazeem Osuolale
- Monitoring and Evaluation Unit, Nigerian Institute of Medical Research, Yaba, Lagos, Nigeria
| | | | - Ngozi Onyia
- Paelon Memorial Medical Center, Victoria Island, Lagos, Nigeria
| | | | - Azuka Patrick Okwuraiwe
- Center for Human Virology and Genomics, Nigerian Institute of Medical Research, Yaba, Lagos, Nigeria
| | - Omoladun Odediran
- Body Soul and Spirit Project, Department of Community Health and Primary Care College of Medicine, University of Lagos, Lagos, Nigeria
| | - Gideon Liboro
- Center for Human Virology and Genomics, Nigerian Institute of Medical Research, Yaba, Lagos, Nigeria
| | - Maureen Aniedobe
- Clinical Diagnostic Department, Nigerian Institute of Medical Research, Yaba, Lagos, Nigeria
| | | | - Stephanie Ogechi Nwaiwu
- Center for Human Virology and Genomics, Nigerian Institute of Medical Research, Yaba, Lagos, Nigeria
| | - Ibukun Ruth Akande
- Center for Human Virology and Genomics, Nigerian Institute of Medical Research, Yaba, Lagos, Nigeria
| | - Rosemary Ajuma Audu
- Center for Human Virology and Genomics, Nigerian Institute of Medical Research, Yaba, Lagos, Nigeria
| | - Babatunde Lawal Salako
- Clinical Science Department, Nigerian Institute of Medical Research, Yaba, Lagos, Nigeria
| |
Collapse
|
3
|
Ndziessi G, Niama RF, Aloumba AG, Peya JM, Ngatse JA, Ngoyomi RA, Niama AC, Tobi N, Loussambou A, Kankou JM, Atipo B, Emeka JC, Ibata P, Moukassa D, Dokekias AE. Seroprevalence of SARS-CoV-2 antibodies in Republic of Congo, February 2022. Epidemiol Infect 2023; 151:e162. [PMID: 37800463 PMCID: PMC10600732 DOI: 10.1017/s0950268823001425] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2022] [Revised: 06/07/2023] [Accepted: 08/07/2023] [Indexed: 10/07/2023] Open
Abstract
In resource-limited countries, the lack of widespread screening masks the true situation of COVID-19. We conducted this study to assess SARS-CoV-2 spread by detection of specific antibodies and to determine associated factors. A population-based cross-sectional study was conducted. Subjects were tested for the presence of two antibodies (IgM and IgG) specific to SARS-CoV-2. Data collection was done using a smartphone with the KoboCollect application. Prevalence of antibodies was estimated with 95% confidence intervals. Logistic regression was used to determine factors associated with positive serological test. A total of 9,094 persons were tested in 4,340 households. The mean age was 30.18 ± 18.65 years, 46.5% male. The overall seroprevalence (prevalence, 95% CI) of SARS-CoV-2 antibodies was (48.2% [47.2%-49.2%]). Being vaccinated, having been in contact with a COVID-19 patient, being older than 50 years, living in a union, having secondary education and having tertiary education were factors independently associated with the likelihood of having anti-sars-CoV-2. We estimate in February 2022 that 48% persons had antibodies against the COVID-19 virus, more among those vaccinated. Vaccination intensification in low prevalence departments will reduce the risk of new outbreaks.
Collapse
Affiliation(s)
- Gilbert Ndziessi
- Department of Public Health, Faculty of Health Sciences, Marien Ngouabi University, Brazzaville, Republic of the Congo
| | - Roch Fabien Niama
- National Laboratory of Public Health, Brazzaville, Republic of the Congo
| | - Axel Gilius Aloumba
- Department of Infectious Diseases, University Hospital of Brazzaville, Brazzaville, Republic of the Congo
| | - Jethro Massala Peya
- Department of Public Health, Faculty of Health Sciences, Marien Ngouabi University, Brazzaville, Republic of the Congo
- Ministry of Public Health and Population, Brazzaville, Republic of the Congo
| | - Joseph Axel Ngatse
- Department of Public Health, Faculty of Health Sciences, Marien Ngouabi University, Brazzaville, Republic of the Congo
- Ministry of Public Health and Population, Brazzaville, Republic of the Congo
| | - Ryschel Alist Ngoyomi
- Department of Public Health, Faculty of Health Sciences, Marien Ngouabi University, Brazzaville, Republic of the Congo
- Ministry of Public Health and Population, Brazzaville, Republic of the Congo
| | - Ange Clauvel Niama
- Department of Public Health, Faculty of Health Sciences, Marien Ngouabi University, Brazzaville, Republic of the Congo
| | - N’Kaya Tobi
- Ministry of Agriculture, Fisheries and Livestock, Brazzaville, Republic of the Congo
| | - Antoine Loussambou
- Ministry of Public Health and Population, Brazzaville, Republic of the Congo
| | - Jean Medard Kankou
- Ministry of Public Health and Population, Brazzaville, Republic of the Congo
| | - Benjamin Atipo
- Ministry of Public Health and Population, Brazzaville, Republic of the Congo
| | - Jean Claude Emeka
- Ministry of Public Health and Population, Brazzaville, Republic of the Congo
| | - Pascal Ibata
- Army Hospital, Brazzaville, Republic of the Congo
| | - Donatien Moukassa
- Clinical and Molecular Biochemistry Unit, Faculty of Health Sciences, Marien Ngouabi University, Brazzaville, Republic of the Congo
| | - Alexis Elira Dokekias
- Department of Medicine, Faculty of Health Sciences, Marien Ngouabi University, Brazzaville, Republic of the Congo
| |
Collapse
|
4
|
Munyeku-Bazitama Y, Okitale-Talunda P, Mpingabo-Ilunga P, Yambayamba MK, Tshiminyi PM, Umba-Phuati A, Kimfuta J, Phukuta FA, Makindu G, Mufwaya-Nsene R, Asari R, Makimoto S, Baketana LK, Ahuka-Mundeke S, Isono M, Nsio-Mbeta J, Makiala-Mandanda S, Muyembe-Tamfum JJ. High Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Prevalence After the Third Epidemic Wave (May-October 2021) in Matadi, Democratic Republic of the Congo. Open Forum Infect Dis 2023; 10:ofad023. [PMID: 36726537 PMCID: PMC9887263 DOI: 10.1093/ofid/ofad023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2022] [Accepted: 01/16/2023] [Indexed: 01/19/2023] Open
Abstract
Background By the end of the third wave of the coronavirus disease 2019 (COVID-19) epidemic (May-October 2021), only 3130 of the 57 268 confirmed cases of coronavirus disease 2019 (COVID-19) in the Democratic Republic of the Congo (DRC) were reported in Kongo Central. This province, and especially its capital city, Matadi, has essential trade and exchanges with Kinshasa, the epicenter of the COVID-19 epidemic in DRC. Kinshasa accounted for 60.0% of all cases during the same period. The true burden of COVID-19 in Matadi is likely underestimated. In this study, we aimed to determine the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence and associated risk factors after the third wave in Matadi. Methods We conducted a population-based cross-sectional study in October 2021. Consenting participants were interviewed and tested using an enzyme-linked immunosorbent assay commercial kit. We applied univariable and multivariable analysis to evaluate factors associated with seropositivity and adjusted the seroprevalence for the test kit performance. Results We included 2210 participants from 489 households. Female participants represented 59.1%. The median age was 27 years (interquartile range, 16-45 years). The crude SARS-CoV-2 seroprevalence was 82.3%. Age was identified as the main risk factor as younger age decreased the seropositivity odds. Accounting for clustering at the household level increased the seroprevalence to 83.2%. The seroprevalence increased further to 88.1% (95% confidence interval, 86.2%-90.1%) after correcting for the laboratory test kit performance. Conclusions The SARS-CoV-2 seroprevalence was very high, contrasting with reported cases. Evidence generated from this population-based survey remains relevant in guiding the local COVID-19 response, especially vaccination strategies.
Collapse
Affiliation(s)
- Yannick Munyeku-Bazitama
- Département de Virologie, Institut National de Recherche Biomédicale, Kinshasa, Democratic Republic of the Congo
- Division of Global Epidemiology, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan
- Département de Biologie Médicale, Faculté de Médecine, Université de Kinshasa, Kinshasa, Democratic Republic of the Congo
| | - Patient Okitale-Talunda
- Département de Biologie Médicale, Faculté de Médecine, Université de Kinshasa, Kinshasa, Democratic Republic of the Congo
| | - Patrick Mpingabo-Ilunga
- Département de Biologie Médicale, Faculté de Médecine, Université de Kinshasa, Kinshasa, Democratic Republic of the Congo
| | - Marc K Yambayamba
- Département d’Epidémiologie et Biostatistiques, Ecole de Santé Publique, Université de Kinshasa, Kinshasa, Democratic Republic of the Congo
| | - Paul M Tshiminyi
- Département de Virologie, Institut National de Recherche Biomédicale, Kinshasa, Democratic Republic of the Congo
| | - Aimé Umba-Phuati
- Division Provinciale de Santé du Kongo Central, Matadi, Democratic Republic of the Congo
| | - Jacques Kimfuta
- Division Provinciale de Santé du Kongo Central, Matadi, Democratic Republic of the Congo
| | - Ferdinand A Phukuta
- Division Provinciale de Santé du Kongo Central, Matadi, Democratic Republic of the Congo
| | - Goethe Makindu
- Division Provinciale de Santé du Kongo Central, Matadi, Democratic Republic of the Congo
| | | | - Ryoko Asari
- Japan International Cooperation Agency, Tokyo, Japan
| | | | - Lionel K Baketana
- Département de Virologie, Institut National de Recherche Biomédicale, Kinshasa, Democratic Republic of the Congo
| | - Steve Ahuka-Mundeke
- Département de Virologie, Institut National de Recherche Biomédicale, Kinshasa, Democratic Republic of the Congo
- Département de Biologie Médicale, Faculté de Médecine, Université de Kinshasa, Kinshasa, Democratic Republic of the Congo
| | - Mitsuo Isono
- Japan International Cooperation Agency, Tokyo, Japan
| | - Justus Nsio-Mbeta
- Direction de Surveillance Epidémiologique, Ministère de la Santé, Hygiène et Prévention, Kinshasa, Democratic Republic of the Congo
| | - Sheila Makiala-Mandanda
- Département de Virologie, Institut National de Recherche Biomédicale, Kinshasa, Democratic Republic of the Congo
- Département de Biologie Médicale, Faculté de Médecine, Université de Kinshasa, Kinshasa, Democratic Republic of the Congo
| | - Jean-Jacques Muyembe-Tamfum
- Département de Virologie, Institut National de Recherche Biomédicale, Kinshasa, Democratic Republic of the Congo
- Département de Biologie Médicale, Faculté de Médecine, Université de Kinshasa, Kinshasa, Democratic Republic of the Congo
| |
Collapse
|